Bank of New York Mellon’s Zenas BioPharma ZBIO Stock Holding History

Bank of New York Mellon’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	70,477 +9,613	+16%	+$191K	﹤0.01%	3012
2026 Q1	$1.19M	Buy	60,864 +9,062	+17%	+$203K	﹤0.01%	3104
2025 Q4	$1.88M	Buy	51,802 +10,114	+24%	+$333K	﹤0.01%	2872
2025 Q3	$925K	Buy	41,688 +3,255	+8%	+$53K	﹤0.01%	3251
2025 Q2	$372K	Buy	38,433 +3,245	+9%	+$31.6K	﹤0.01%	3676
2025 Q1	$278K	Sell	35,188 -756	-2%	-$5.92K	﹤0.01%	3738
2024 Q4	$294K	Buy	+35,944	New	+$561K	﹤0.01%	3792

Other funds holding ZBIO

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's ZBIO Position: Q2 2026 in Review

Bank of New York Mellon increased its Zenas BioPharma (ZBIO) stake by 16% in Q2 2026, buying an estimated $191K and bringing the position to 70,477 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Bank of New York Mellon first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.88M in Q4 2025. 62 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Bank of New York Mellon held 70,477 shares of Zenas BioPharma worth $1.79M as of Q2 2026.
Bank of New York Mellon bought 9,613 Zenas BioPharma shares in Q2 2026, an estimated $191K.
Zenas BioPharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3012 holding.
Bank of New York Mellon first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
Bank of New York Mellon's Zenas BioPharma position peaked at $1.88M in Q4 2025.
62 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.